Surgery Partners, Inc. (NASDAQ: SGRY), a key player in the healthcare sector, specializes in owning and operating a diverse network of surgical facilities across the United States. With a market capitalization of $2.1 billion, the company positions itself as a significant entity within the medical care facilities industry. Investors interested in the healthcare domain might find Surgery Partners an intriguing opportunity, especially given its potential upside of 16.04%, as reflected in the average analyst target.
Currently trading at $16.06, Surgery Partners has experienced a modest price change of 0.66 (0.04%). Its 52-week range reveals a low of $11.49 and a high of $23.84, indicating a relatively volatile year for the stock. Despite this volatility, the stock’s current price remains above key technical indicators, with the 50-day moving average at $15.13 and the 200-day moving average at $15.46. The relative strength index (RSI) of 58.82 places it in neutral territory, suggesting that the stock is neither overbought nor oversold at this time.
From a valuation perspective, Surgery Partners presents a mixed picture. The trailing P/E ratio is currently unavailable, which often indicates that the company is not profitable on a net income basis. However, the forward P/E of 24.02 suggests that analysts are projecting earnings growth over the coming year. Investors should note the absence of a PEG ratio and other valuation metrics, which may make it difficult to compare SGRY directly with peers.
Performance metrics further highlight both challenges and opportunities for Surgery Partners. The company boasts a revenue growth rate of 4.50%, which is a positive indicator of its ability to expand its operations. However, the negative earnings per share (EPS) of -0.59 underscores ongoing profitability challenges. The return on equity stands at a modest 2.75%, which may not be particularly compelling for investors seeking high returns. On the positive side, a robust free cash flow of $199 million provides a cushion for strategic investments and operational flexibility.
Surgery Partners does not currently offer a dividend, with a payout ratio of 0.00%. This aligns with its focus on reinvesting earnings into growth and expansion initiatives, rather than returning capital to shareholders. For income-focused investors, this could be a consideration when evaluating the stock.
The analyst community generally holds a favorable view of Surgery Partners, with nine buy ratings and three hold ratings, and no sell ratings. The target price range is set between $14.00 and $24.00, with an average target of $18.64, reflecting optimism about the company’s future performance. This sentiment is mirrored in the potential upside of 16.04% from the current price, offering an attractive prospect for growth-oriented investors.
As a company founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners offers a comprehensive suite of services, including ambulatory surgery centers, surgical hospitals, and a range of ancillary services. Its focus on non-emergency surgical procedures across various specialties positions it well to capitalize on the growing demand for outpatient surgical care.
For investors considering a stake in the healthcare sector, Surgery Partners, Inc. presents an intriguing opportunity with potential for significant upside. However, it’s crucial to weigh the company’s current profitability challenges against its strategic growth initiatives and market position. As always, conducting thorough due diligence and consulting with a financial advisor is recommended before making any investment decisions.
